Internet Drug
Pharmaceutical News & Information; Updated Daily

Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
¿Your Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)

1/20 Price's Office Pushed AHRQ to Remove BiDil Study from Site
When a Study Cast Doubt on a Heart Pill, the Drug Company Turned to Tom Price .... After hearing from a company whose CEO was a campaign contributor, a congressional aide to Donald Trump's HHS nominee repeatedly pushed a federal health agency to remove a critical drug study from its website. .... ProPublica

1/20 73% of Seniors in Part D Plans Enrolled in Narrow Networks
New 2017 Part D Enrollment Data: Walgreens and Walmart Trounce CVS in Preferred Networks .... The three biggest companies—Humana, UnitedHealthcare, and CVS Health's SilverScript—now account for 69% of enrollment in stand-alone Part D plans .... Drug Channels

1/20 Trulance Gets FDA OK
FDA approves Trulance for Chronic Idiopathic Constipation .... Participants receiving Trulance were more likely to experience improvement in the frequency of complete spontaneous bowel movements than those receiving placebo, and also had improvements in stool frequency and consistency and straining .... FDA News Release

1/20 FDA Sets "Consistent with Label" Test for Promotions
In draft guidance, the FDA defines appropriate off-label comms as being 'consistent' with the label .... The agency cited a number of examples of ways pharma companies can share information: how a product performs in specific patient subgroups within its approved-patient population; data about long-term safety and efficacy of products that treat a chronic condition; updates from head-to-head trials for drugs with the same approved indication; and providing additional context about a drug's mechanism of action .... MM&M

1/20 FDA Gets Everything Out the Door Before the New Administration: Report Released on Phase 2 vs Phase 3 Differing Results
22 Case Studies Where Phase 2 and 3 Results Diverge: New FDA Report .... Of the 22 case examples, Phase 3 studies did not confirm Phase 2 findings of effectiveness in 14 cases, safety in one case, and both safety and effectiveness in seven cases .... Regulatory Focus

1/20 AEs Reported with Lemtrada
Researchers Report Severe Adverse Effects of MS Drug Alemtuzumab .... Using magnetic resonance imaging, the researchers discovered a new mode of inflammation: they found areas in the brain with numerous ring-enhancing lesions. The patients had not displayed this pattern in their previous medical histories .... PTCommunity

1/20 Frazier: Keytruda + Chemo Could Be Cheaper than Other Lung Cancer Options
Merck CEO sees Keytruda in pole position in cancer race .... The FDA is due to decide by May 10 whether to approve a combination of the immune system-boosting drug with chemotherapy as an initial therapy for advanced lung cancer .... Reuters

1/20 "Valeant Strategy" for Auvi-Q: Only a Few Chumps Pay List Price
In Rube Goldberg Price Scheme, EpiPen Competitor Auvi-Q To Be Free For Patients, $4,500 For Their Insurers .... Kaleo, Auvi-Q's manufacturer, will charge patients who have commercial insurance $0 for the product, whether or not the insurance company pays for it. It will also give the product away to families with an income of less than $100,000.... But the list price for Auvi-Q, and the starting point for insurance companies, will be much higher: $4,500 .... Forbes (autoplay ad)

1/20 Price Won't Let Himself Get Pinned Down on Price Negotiations
Tom Price, nominee to lead HHS, sidesteps questions on Medicare drug-pricing negotiations .... After initially sidestepping questions on drug-price negotiations, he seemed to suggest that the policy would at least be considered, given Trump's outspoken support for it, but he expressed no enthusiasm .... Stat News

1/20 New Lineup at Top of GSK
GSK grabs Astra executive to replace pharma head .... GlaxoSmithKline's global head of pharmaceuticals, Abbas Hussain, is to leave Britain's biggest drugmaker after being passed over for the top job and will be replaced by Luke Miels from AstraZeneca. .... Reuters

1/20 Internet Drug News Fast Takes:
6 experts weigh in on how Obama changed health care
Advisory Board
What Trump's Libertarian Pals Don't Understand About The FDA -- Or Reality
Forbes/Matthew Herper
Novartis chief Jimenez touts two top PhIII drug prospects
Endpoints News
U.S. Health Agency Tells Grassley There Is No EpiPen Deal Yet
NY Times
Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump
Investors Business Daily

1/19 Drugmakers Lose 37% of List Price to Rebates, Discounts
Secret Rebates Erode Drugmaker Revenue, Industry Study Says .... Of the estimated $349.1 billion that insurers and patients paid for brand-name drugs in 2015, $218.6 billion, or 63 percent, was realized as revenue by drugmakers.... In 2013, pharma companies kept $177.5 billion, or 67 percent, of the $264.9 billion in gross expenditures .... Bloomberg

1/19 Novartis CEO: If America is Back for Business, We'll Be There
Trump tax cuts could mean more Novartis investment in U.S. .... "When we build a new manufacturing site we think about the tax rate, we think about the economy of the country, we think about jobs, so a booming U.S. economy would make the U.S. more attractive for investment," Joe Jimenez said .... Reuters

1/19 Mallinkrodt Pays for Strangling Rival in its Cradle
Mallinkrodt Reaches $100 Million Settlement with FTC .... Irish drugmaker Mallinkrodt has agreed to pay $100 million to settle Federal Trade Commission charges that it violated antitrust laws by buying the rights to an infantile-spasms drug that threatened its own rival product Acthar .... The Street (autoplay video)

1/19 Twittering Docs Don't Reveal Their COIs
What Your Doctor Isn't Telling You on Twitter .... Cancer doctors with Twitter accounts have something else in common: more than 70% of them receive funding from drug companies .... Time

1/19 FDA Sets High Hurdles for Biosimilars
FDA Issues Long-Awaited Biosimilar Interchangeability Guidance .... The guidance... recommends that sponsors looking to get a biosimilar approved as interchangeable with its reference product conduct one or more switching studies to show that patients can alternate between the two products safely and without diminished efficacy .... Regulatory Focus

1/19 "The Medicine Was So Good, I Bought the Company": Pundits Say if US Govt Bought Gilead, Cost to Treat Hep C Would Drop to a Third
Should the U.S. try M&A to save on hep C? Gilead would be a good buy, experts say .... Gilead's current market cap is about $100 billion. Offering a 30% premium to shareholders, and assuming the company's $26 billion in debt, would cost the U.S. $156 billion. But the government could, by paring away Gilead's portfolio and repatriating its foreign cash—tax-free, of course—lower that cost by more than two-thirds .... Fierce Pharma

1/19 FDA Appeared to Ramp Up Enforcement Letters in 2016
The FDA targeted DTC, video, unapproved drug promotion in 2016 .... The FDA is taking a closer look at how drugmakers use channels like direct-to-consumer advertising and video, a shift that has raised questions for pharmaceutical marketers .... MM&M

1/19 Durvalumab Delay Leaves AZN Behind the Pack in Immune-Oncology Race
AstraZeneca's Catch-Up Strategy is Falling Behind .... One of Astra's chosen paths to $40 billion was to become a major player in the rapidly growing IO market, which neared $10 billion in total sales last year. This approach was always a longshot, though... Astra's lead drug durvalumab is still awaiting its first approval .... Bloomberg Gadfly

1/19 2 for 5: In First Round of Testing, Most Attempts to Replicate Cancer Studies Fail
What Does It Mean When Cancer Findings Can't Be Reproduced? .... The first results from a major project to measure the reliability of cancer research have highlighted a big problem: Labs trying to repeat published experiments often can't. .... NPR Shots blog

1/19 Exclusivity Extensions Pay Off
US Six-Month Drug Market Exclusivity Extensions Could Yield Nearly $100 Million .... The median discounted financial gain for each drug would have been $94.6 million, with blockbuster drugs predictably enjoying the highest returns. The authors’ analysis also suggests that manufacturers had spent a median of $29.8 million on trials that gained supplemental approval for rare disease indications. .... Health Affairs blog

1/19 Internet Drug News Fast Takes:
New prescription: Doctor offices that look like Apple stores
Sanofi wins EU approval for new diabetes combination Suliqua
Can marijuana treat MS symptoms? It's hard for researchers to find out
The Conversation
A third of asthma patients are misdiagnosed, study finds
Medical News Today

Fast Takes
CME providers use Facebook Live to educate doctors
Medical Marketing & Media
India clamps down on OTC antibiotic sales to stem spread of superbugs
Iun Pharma Technologist
Pfizer Continues to Fade -- Get Ready to Buy on the Dip
The Street
Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients
The Street
Former Drug Rep Plans On Running For Boston Mayor
Boston Globe
FDA approves generic version of Jazz Pharma's sleep disorder drug Xyrem (sodium oxybate)

1/17 McKesson Pays $150 Million To Settle Allegations Regarding Narcotic Reporting
McKesson in record $150 million U.S. settlement over suspicious drug orders …. processed over 1.6 million orders for controlled substances from June 2008 through May 2013, yet only reported 16 as suspicious … [Reuters]

Biogen Pays Forward $1.25 Billion In License Fees To Settle
Tecfidera (dimethyl fumarate) Patent Dispute
Biogen to pay $1.25b to settle patent dispute … Biogen's settlement with Forward Pharma was expensive, but has the potential to extend the patent life of Tecfidera from 2022 to 2026 or 2028… challenged a Biogen patent on the ingredient, claiming it owned a patent preceding Biogen's … [Boston Globe]

JAMA Implies Pharma Has Pervasive Influence On Treatment Guidelines, Etc.
From Twitter To Treatment Guidelines, Industry Influence Permeates Medicine … continues to pervade practically every area of medicine, reaching those who write guidelines that shape doctors' practices, patient advocacy organizations, letter writers to the Centers for Disease Control and Prevention  …[NPR]

Harris Poll: >90% Believe Pharma Cares More About Money Than People
Harris Poll: Only Nine Percent of U.S. Consumers Believe Pharma and Biotechnology Put Patients over Profits; Only 16 Percent Believe Health Insurers Do …   "Consumers see no safe port, no place where their interests are truly protected - and that lack of consumer trust is reflected in the reputational risk we see across the U.S. health care landscape … [Harris Poll]

Kaiser: Orphan Drug Program Broke, 1983 Law Needs Fixing
- Claims Pharma exploits loopholes to extend exclusivity for common drugs
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies … system intended to help desperate patients is being manipulated by drugmakers to maximize profits and to protect niche markets for medicines already being taken by millions … [Kaiser Health News]

How The Affordable Care Act Protects Rare Disease Drugmakers
- Pre-existing condition clause of ACA guarantee market for expensive specialty meds
Trump administration raises questions for rare-disease drugmakers … marketers and brand stewards in the realms of rare and orphan diseases might want to prepare themselves for the worst-case scenario: sharply curtailed protections for patients with pre-existing conditions … [Medical Marketing & Media]

15 Top Selling Cancer Meds Expected To Rake In $90 Billion By 2020
- Immune system modulated products (checkpoint inhibitors) drive this market
The top 15 best-selling cancer drugs in 2022 … $90 billion in sales. To put that in perspective, that represents about one-fourth of the entire U.S. pharma market in 2014, according to QuintilesIMS  … [Fierce Pharma]

Fast Takes
Trump plays the Medicare negotiations card
Endpoints News
Silicon Valley Exec Meets Trump for top FDA Job
Bristol-Myers Threatens Merck's 'Head Start' In Lung Cancer: Analyst
Investor's Business Daily
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

Trump Twitter-shames Pharma; Will It Work?
- Pharma joins auto, airplanes & Mexico
Trump's latest pharma-fighting plan? Use Twitter to force prices down, manufacturing to U.S. … declared he'd institute competitive bidding to control the prices government programs pay for drugs, he reverted over the weekend to Medicare price negotiation … [Fierce Pharma]

Analyst: Odds Against Regeneron, Sanofi In Amgen PCSK9 Patent Battle
Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink … Specialists believe "regardless of the ultimate merits of Regeneron and Sanofi's case, they will face an unprecedented (and probably first) branded pharmaceutical product withdrawal … [Investor's Business Daily]

Glaxo, Lilly, Novartis Lose Exclusivity On Important Products In 2017
5 Drug Patents Expiring in 2017 … Merck has the maximum number of four drug patents expiring in 2017, representing around $3.8 billion or 10% of its total annual revenue, GlaxoSmithKline has three, and Eli Lilly has two … [Investopedia]

Wanted: New Generation Of Antidepressants
For Refractive Patients
No new antidepressants in sight despite growing need, experts warn … depression and anxiety rates are increasing across the world … up to half of all people treated fail to get better with first-line antidepressants … [Reuters]

1/17 Inhaled Epinephrine: Mannkind's New Brainchild?
- Didn't work out so well for insulin; is there a market for this product?
MannKind 'aggressively' moving forward with inhalable epinephrine … people are reluctant to either stab themselves in the leg with this rather scary looking needle or the cost of at $250 or $300 a pop … [In-Pharma Technologist]
Editor's Note: In light of the $100 Impax Epi-Pen copycat, will this product fulfil an unmet need?   

Novartis Reaches For Pharma's Holy Grail - Weight Loss Med
Novartis to Conduct Trial on Obese, Type II Diabetes Patients … phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes … [NASDAQ]
Editor's Note:  Last Spring, the above cited drug, bimagrumab, had been examined as a treatment for a rare muscle wasting disease but it failed to reach  its primary endpoint.

1/16 Fast Takes
Is Donald Trump Big Pharma's Worst Nightmare?

Motley Fool
Trump Just Leveled Drug Companies With These 4 Words
Motley Fool
FDA rejects TESARO's marketing application for nausea drug rolapitant IV
Seeking Alpha
Shire to fork over $350M to settle 'flagrant' Dermagraft kickback claims
Fierce Pharma

Supremes Agree To Review Law Governing Copycat Biotech Meds
Amgen Fight Over Copies of Biotech Drugs Gets High Court Review …  Supreme Court agreed to hear a dispute that could help clarify the steps needed to get low-cost alternatives to pricey biotechnology drugs on the market … [Bloomberg]
U.S. Supreme Court agrees to hear dispute over biologic drug sales … [Reuters]

Nevada Woman Died From Superbug; Resistant To Every Antibiotic
- 70-year old Nevada woman died in September; Klebsiella pneumoniae
A Nevada woman dies of a superbug resistant to every available antibiotic in the US … woman who had spent considerable time in India, where multi-drug-resistant bacteria are more common than they are in the US … developed a bone infection in her femur and her hip and was hospitalized a number of times in India in the two years that followed … [Pharmalot]

Lilly Wins Appeal:  Alimta Patent Safe Till 2022
Pending Review By Patent and Trademark Office
- Teva indulged in patent infringement of Lilly's third biggest product
Lilly Jumps After Lung Cancer Drug Patent Upheld … While Thursday's appeals court decision covers the district court case, the patent also is being reviewed by the U.S. Patent and Trademark Office. The agency, which uses a different legal standard than courts, is expected to release its final decision by June … [Bloomberg]

Biogen Defends Drug's $750K Price Tag
- Worth the price due to 47% relative risk reduction of  death from rare genetic ailment
New Spinraza Data Has Biogen Screaming 'It's Worth It!' … approximately 1,700 patients will start Spinraza treatment in 2017 and 2018 … infants in the trial who did not receive the drug, 68 percent either died or needed permanent ventilation. In the portion receiving the drug, only 39 percent died or required permanent ventilation … [Biospace]

'Meaningless Suffixes' Slammed by Industry in FDA Naming Guidance
- Claim 4-letter suffix should refer to manufacturer, not be random
'Meaningless suffixes' slammed by industry in FDA naming guidance … Pfizer believes the suffix should be meaningful - derived from or in some way related to the license holder name - or a single random company-specific suffix that would become meaningful over time… [Biopharma Reporter]

1/13 FDA Sets Biosimilar Naming Rules: Four Characters of Alphabet Soup at the End
Non-Proprietary Naming of Biologics and Biosimilars: FDA Finalizes Guidance .... The FDA has finalized long-awaited guidance on how biosimilars and their biologic reference products' names should include a four-letter, FDA-designated meaningless suffix attached at the end of the nonproprietary name .... Regulatory Focus

1/13 ACP and AAFP Diabetes Guidelines Not Friendly to New Agents
Physicians group urges metformin rather than new drugs .... The group said patients with Type 2 diabetes should begin treatment with metformin... after first trying to change their lifestyle habits.... if clinicians consider adding a second drug, like an SGLT2 inhibitor or DPP-4 inhibitor, they should also take into account that the "increased cost may not always support the added benefit" .... MM&M

1/13 Pfizer CFO Looking for New Deals
Pfizer wants you. And you. And you. And you. .... Pfizer CFO Frank D'Amelio said they're on the lookout for new deals that will grow revenue "now or soon," but frankly are still interested in early-stage efforts as well .... Endpoints

1/13 Insights from the 2016 Willis Towers Watson Employer Survey
Infographic: Employers act to control pharmacy trend .... A surge in specialty pharmacy requires companies to employ a host of approaches, emphasizing specialty pharmacy utilization in order to be a best performer. .... Willis Towers Watson

1/13 $110 Generic for EpiPen, Now at CVS
CVS generic competitor to EpiPen, sold at a 6th the price .... The drugstore chain says it will charge $109.99 for a two-pack of the authorized generic version of Adrenaclick, a lesser-known treatment compared to EpiPen, which can cost more than $600 .... AP (Autoplay video)

1/13 Memo to the PEOTUS: Manufacturing Overseas in the Norm, and Saves US Patients Money
Trump's Plan to Cut Drug Imports Could Raise Prices, Not Lower Them .... American imports of statins, anticonvulsants and insulins have doubled, while imports of proton-pump inhibitors have risen sixfold over the past five years. The imports consist heavily of generic drugs, and three-fifths come from India, although Eastern Europe has become an increasingly important supplier .... NY Times

1/13 States Enacting Laws Mandating Birth Control Coverage
U.S. states mull contraception coverage as Obamacare repeal looms .... Growing numbers of U.S. states are seeking to ensure that women have continued access to free birth control in case the insurance benefit is dropped as part of President-elect Donald Trump's vow to repeal and replace the Affordable Care Act .... Reuters

1/13 Type 2 Diabetes in Kids Has Doubled in Last 5 Years; Obesity Up Sharply
Type 2 diabetes shows marked increase in pediatric population .... Private health insurance claim lines with a type 2 diabetes diagnosis more than doubled in the pediatric population (ages 0 to 22 years) from 2011 to 2015 .... FAIR Health

1/13 Alimta, Lilly's Third Biggest Seller, Protected Through May 2022
Lilly Jumps After Lung Cancer Drug Patent Upheld .... The patent covers a way of administering the chemotherapy treatment, where it's given after pretreatment with specific vitamins to reduce the toxicity of the main compound, pemetrexed .... Bloomberg

1/13 Class Action Against Novo
Amid insulin market scrutiny, Novo faces class action alleging 'collusive price fixing' .... A New York law firm has filed a class action suit against the Danish pharma for its role in alleged "collusive price fixing" .... Fierce Pharma

1/13 Pundit: Pharmaceutical Innovation is About to Run Out of Steam
Researcher says pharma industry's ability to deliver new drugs may be coming to an end .... The biotechnology sector was responsible for more than two-thirds of all new medicines in the past decade... but the number of successful biotech companies peaked at 141 in 2000 and had fallen to 60 by the end of 2014. It is simply easier and less risky for venture capitalists to invest in two guys in a garage writing code ... than in a large, complex biotech lab .... Medical Xpress

1/13 Internet Drug News Fast Takes:
Trump taps former Beth Israel CEO David Shulkin to lead VA
Advisory Board Daily Briefing
N.Y. governor clamps down on drug pricing
Chain Drug Review
Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo
Meet AstraZeneca's New Head of Oncology
Can wearable sensors tell when you're sick?

1/12 Trump Says Pharma Will Have to Bid for Govt. Business
Drug Stocks Plunge as Trump Threatens to Force Price Bidding .... "[Drug companies are] getting away with murder," Trump said at a press conference in New York. "Pharma has a lot of lobbyists and a lot of power and there is very little bidding. We're the largest buyer of drugs in the world and yet we don't bid properly and we're going to save billions of dollars." .... Bloomberg (autoplay video)

Trump's Comments Are Big Pharma's Nightmare .... There are plenty of steps a Medicare administrator motivated by working for an angry Donald Trump could take to hurt a drug company whose price had been deemed too high .... Forbes/Matthew Herper

1/12 Cigna Will No Longer Cover EpiPen; Impax Generic Device is Substitute
Key Insurer Drops Mylan's EpiPen as Bresch Reflects on Tumultuous 2016 at JPM .... The move was effective as of Jan. 7, when Cigna released a list of changes to coverage for 2017 .... The Street (autoplay video)

1/12 High Deductible Plans Not the Obstacle to Care That Some Had Feared
How do higher deductibles impact care for chronic disease? .... The switch to insurance with higher out-of-pocket costs wasn't tied to meaningful changes in how often these diabetics got outpatient checkups or tests to monitor their disease.... But after the switch, emergency department visits for preventable diabetes complications spiked for poor patients .... Reuters

1/12 AbbVie Takes the 10% Pledge
AbbVie vows to keep drug price increases below 10 percent .... AbbVie, whose rheumatoid arthritis treatment Humira is the world's biggest-selling drug, joins Allergan and Danish diabetes company Novo Nordisk as the first major drugmakers promising such a limit on price increases .... Reuters

1/12 ECRI's "Top Ten Hospital C-Suite Watch List"
Top 10 healthcare technology advances for 2017, according to ECRI .... Liquid biopsies, opioid addiction biosensors and AI top ECRI's annual list of technologies that will transform the industry this year .... Health IT News

1/12 Pipeline Dry; No New Antidepressants Expected for 10 Years
No new antidepressants in sight despite growing need, experts warn .... Treatment for depression usually involves either medication, some form of psychotherapy, or a combination of both. But up to half of all people treated fail to get better with first-line antidepressants, and around a third of patients are resistant to relevant medications .... Reuters

1/12 Half of Employers Now Employ a Limited Pharmacy Network
Yes, Commercial Payers Are Adopting Narrow Retail Pharmacy Networks .... Preferred network models have grown most rapidly within the Medicare Part D program, where CMS now calls them preferred cost sharing networks. About 85% of Medicare Part D regional prescription drug plans (PDP) have a preferred network .... Drug Channels

1/12 PhRMA Wants to Talk About Research, Not Prices
Here's How Big Pharma Plans To Clean Up After Martin Shkreli .... PhRMA says it plans to launch a national ad campaign, worth tens of millions of dollars a year, to promote the industry's achievements. .... BuzzFeed

1/12 Medication Costs Now at Forefront for Oncologists
Drug Costs -- The No. 1 Challenge in Cancer Care .... In this year's survey, 83% of respondents identified drug costs as their primary concern, which was nearly twice that (45%) from last year's survey. .... Medscape

1/12 Handy Graphic to Help Compare Health Reform Proposals
Click on image, then click again, to embiggen

1/12 Internet Drug News Fast Takes:
Trump meets with two contenders to lead NIH
Study finds how stress raises heart disease and stroke risk
FDA's Human Drug Compounding Progress Report [link is PDF]
IBM Watson, FDA to explore blockchain for secure patient data exchange
Computer World
National Cancer Institute and drug companies aim to speed up clinical trials
Washington Post

1/11 Express Scripts Choking Off Small Specialty Pharmacies; Moving Patients to Accredo
Specialty Pharmacies Say Benefit Managers Are Squeezing Them Out .... Prime Aid and other independent pharmacies say that Express Scripts is unfairly wielding that market power to steer business to Accredo. Express Scripts patients typically cannot have their drugs covered by insurance if they use a pharmacy that is not in the network .... NY Times

1/11 Quick Review (May 10) for Keytruda with Chemo as First-Line for Advanced Lung Ca
FDA accepts Merck application for lung cancer combo therapy .... This first application for Keytruda in combination with another medicine would include patients with metastatic or advanced non-squamous non-small cell lung cancer (NSCLC) regardless of PD-L1 expression level, opening up a much larger market for the medicine .... Reuters

1/11 J&J Will Publish Prices, Both List and Discounted
Johnson & Johnson to Report Average Increases in List Prices for U.S. Drugs .... The report will give the average increase in the list prices for all company drugs in the U.S., as well as their average price after the discounts given by the company.... The report will also show that J&J spends more on research than marketing .... WSJ$$

1/11 Cardiovascular Market Overview
When it comes to PCSK9s, payers resisted — and sales flopped .... As attention increasingly shifts to the enormous need — and tremendous ROI — in the autoimmune and oncology sectors, the development of CV drugs has fallen out of favor, even as heart disease and stroke remain top killers in the U.S. .... MM&M

1/11 Clip 'N Save
Top 25 cardiovascular brands, 2015-2016 .... MM&M

1/11 Heritage Pharmaceutical Execs Plead Guilty
Ex-N.J. pharma execs admit to fixing generic drug prices .... Glazer, 45, and Malek, 40, who are brothers-in-law, are believed to be cooperating with federal investigators as focus shifts to larger firms and what role they may have played in the antitrust scheme .... Philadelphia Inquirer

1/11 Dendreon (Maker of Provenge) Sold to Chinese Firm
Debt-Ridden Valeant (VRX) Offloads Dendreon (DNDN) for $819.9 Million Cash .... Valeant acquired Dendreon in February 2015 for $400 million in a stalking horse bid after the Seattle-based company declared bankruptcy .... Biospace

1/11 Califf Out on Jan. 20; No Word Yet on New Appointment
FDA's Califf, ONC's Washington are done .... FDA Commissioner Robert Califf, who didn’t take office until September 2015 and wasn’t confirmed until February, won’t have a chance to expand his innovative plans for the agency, despite enjoying bipartisan support .... Politico

1/11 Secretive Messenger RNA Company Beginning with Vaccines
Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline .... The company now has five vaccines in clinical trials. Two are for strains of influenza that could become pandemic, for which governments might want to stockpile vaccines. Another is for Zika virus, and a fourth, being developed with AstraZeneca, would treat heart attacks .... Forbes/Matthew Herper

1/11 "Safer" Oxycontin Drove Thousands to Heroin
How an 'abuse-deterrent' drug created the heroin epidemic .... The working paper, published this week by the National Bureau of Economic Research, shows that the Oxycontin reformulation was by far the single largest driver of the shift to heroin, accounting for "as much as 80% of the three-fold increase in heroin mortality since 2010" .... Washington Post

1/11 Internet Drug News Fast Takes:
Biden vows to push pharmaceutical companies to 'ensure patients can afford treatments'
Size matters: Study shows big difference in office visit reimbursements
Cancer Death Rate Has Dropped 25% Since 1991 Peak
American Cancer Society news release
Mammograms tied to overdiagnosis of breast cancer
Pharmacy chains point to rising flu activity
Chain Drug Review
After amputation, you may be able to take your body part home

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 1/16/2017

If your intellectual property being infringed
e-mail the webmaster and we will   
fix it. 

The information on this site is not meant as medical advice.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

The information contained on this web site is for your information only.  You should never take a drug without a doctor's prescription - only an idiot does that.   
Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

Do NOT start or stop taking a medicine based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Namhman Licensed Pharmacist (State Of NY; Lic #035512)

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!